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Coenzyme Q (CoQ) is present in all cells and membranes and in addition to be a member of the mitochondrial respiratory chain it has also
several other functions of great importance for the cellular metabolism. This review summarizes the findings available to day concerning
CoQ distribution, biosynthesis, regulatory modifications and its participation in cellular metabolism. There are a number of indications that
this lipid is not always functioning by its direct presence at the site of action but also using e.g. receptor expression modifications, signal
transduction mechanisms and action through its metabolites. The biosynthesis of CoQ is studied in great detail in bacteria and yeast but only
to a limited extent in animal tissues and therefore the informations available is restricted. However, it is known that the CoQ is
compartmentalized in the cell with multiple sites of biosynthesis, breakdown and regulation which is the basis of functional specialization.
Some regulatory mechanisms concerning amount and biosynthesis are established and nuclear transcription factors are partly identified in this
process. Using appropriate ligands of nuclear receptors the biosynthetic rate can be increased in experimental system which raises the
possibility of drug-induced upregulation of the lipid in deficiency. During aging and pathophysiological conditions the tissue concentration of
CoQ is modified which influences cellular functions. In this case the extent of disturbances is dependent on the localizaion and the modified
distribution of the lipid at cellular and membrane levels.
D 2003 Elsevier B.V. All rights reserved.Keywords: Coenzyme Q; Antioxidant; Mevalonate pathway; Aging; Cardiovascular diseaseCoenzyme Q (CoQ) was isolated and characterized by
Festenstein et al. in 1955 [1] and it was established in 1957
by Crane et al. [2] that this compound functions as a
member of the mitochondrial respiratory chain. Wolf et al.
[3] determined its complex structure in 1958. CoQ was
found to be an unusual lipid since the redox active benzo-
quinone ring is connected to a long isoprenoid side chain,
requiring specific placements in a biological membrane. At
this time only the redox function of this lipid was studied
while its function as an antioxidant was investigated mainly
during the past 15 years. In the initial period, the concept of
CoQ distribution and synthesis was attributed exclusively to
the inner mitochondrial membrane. This appeared to be
reasonable since the only known function at this time was
shuttling electrons from complexes I and II to complex III in
the mitochondrial electron transfer system.0005-2736/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2003.11.012
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respiratory chain was proven by several facts, such as
depletion and reincorporation of the lipid into submitochon-
drial particles causing inactivation and reactivation of
NADH and succinate dehydrogenas activities [4]. In 1975
Mitchell [5] proposed the protonmotive Q cycle, the cyclic
electron transfer pathway through complex III involving
ubisemiquinone, a proposal generally accepted. The role of
CoQ in the mitochondrial respiratory chain and associated
oxidative phosphorylation is studied in great details by
many investigators and is not discussed here. There are
recent and excellent reviews about this subject which are
recommended to consult [6–9].1. Functions of CoQ
In addition to its central role in the mitochondrial
respiratory chain, CoQ is now involved in a number of
aspects of cellular metabolism and we can expect that
Table 1
Functions of coenzyme Q
. Participation as electron carrier in the mitochondrial respiratory chain
. Participation in extra-mitochondrial electron transport (PLMa, lysosomes)
. Endogenously synthesized, lipid-soluble antioxidant
. Regulation of mitochondrial permeability transition pores
. Required for activation of mitochondrial uncoupling proteins
. Regulation of the physicochemical properties of membranes
. Modulation of the amount of h2-integrins on the surface of blood
monocytes
. Improvement of endothelial dysfunction (probably by increasing nitrogen
oxide)
. Oxidation of sulfide (in yeast)
. Introduction of disulfide bonds (in bacteria)
a Plasma membranes.
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(Table 1).
1.1. The plasma membrane redox system
The plasma membrane of eukaryotic cells contains an
NADH oxidase (NOX) that is involved in the transfer of
electrons across the membrane (Fig. 1). The name of this
enzyme was given in the initial period of studies, when it
was believed that the function of the enzyme is the oxidation
of the externally added NADH. The NOX protein is not a
transmembranous protein but is located at the external
surface of the plasma membrane [10]. It has both hydro-
quinone (or NADH) oxidase and protein-disulfide-thiol
interchange activities that have been shown to respond to
hormones and growth factors [11,12]. The NOX protein is
not related to the NADPH oxidase found in neutrophils,
which is not dependent of CoQ [13]. At the cytosolic
surface, a quinone reductase is present that catalyzes the
reduction of CoQ in the presence of NADH [14]. This
system together with the enzymatic mechanisms discussed
in Section 7 are responsible for regeneration of cellular
reduced CoQ. The participation of CoQ in the plasma
membrane electron transport was shown by the fact that
the NOX activity was inhibited by removal of CoQ with 
 
Fig. 1. Schematic representation of the CoQ-dependent trans-plasma membrane e
reductase is present that reduces CoQ to ubiquinol (CoQH2). CoQH2 shuttles the
(Asc), produce superoxide (O2
), reduce O2 to water and reduce protein disulfideheptane and reconstitution of the activity by CoQ addition
[15]. Several terminal electron acceptors have been sug-
gested, such as molecular oxygen, protein disulfides or
ascorbyl radicals [15–17].
The function of NOX is proposed to be related to the
control of cell growth and differentiation as well as main-
taining extracellular ascorbate in reduced form [18,19].
Another possibility is that the CoQ-dependent NOX is
involved in the regulation of the cytosolic NAD+/NADH
ratio. In fact, Larm et al. [20] and Lawen et al. [21] showed
that U0 cells, lacking mitochondrial DNA, accumulate
NADH as a result of glycolytic production of ATP and that
the plasma membrane oxidoreductase system is able to
reoxidize the NADH in these cells. Finally, Crane et al.
[22] proposed yet another two functions for CoQ in the
plasma membrane electron transfer system. First, the redox
state of CoQ may act to control a tyrosine kinase in a
manner analogous to that found in Escherichia coli [23].
Second, oxidation of the semiquinone in the plasma mem-
brane could generate H2O2 and it has been shown that
activation of peroxide generation, by for instance xanthine
oxidase, induces tyrosine kinase and early gene expression
[24,25].
Recently it was also suggested that lysosomes contain
an NADH-dependent CoQ reductase involved in translo-
cation of protons into the lysosomal lumen [26]. Appar-
ently, at this location the reduction of CoQ occurs in two
subsequent one-electron transfer steps involving FAD and
cytochrome b5 with molecular oxygen as the terminal
electron acceptor. Though intriguing, further research will
be necessary to define the function of this CoQ-dependent
lysosomal reductase.
1.2. Antioxidants and generation of reactive oxygen species
(ROS)
Eighty percent of the normal mammalian oxygen con-
sumption occurs in mitochondria, of which 80% is coupled to
ATP production [27,28]. ROS account for 1–2% of the 
 
lectron transport. At the cytosolic side of the plasma membrane, a quinone
electrons to the NOX that is able to reduce extracellular ascorbyl radicals
s. The figure is adopted from Morre´ et al. [317].
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considered to be the major source of O2
S and H2O2 produc-
tion in the cell [29,30]. The leakage of electrons from the
respiratory chain result in a 5–10-fold higher steady-state
concentration of O2
 in the mitochondrial matrix than in the
cytosolic and nuclear spaces [31]. The formation of mito-
chondrial ROS is dependent on the state of respiration, i.e. in
state 4, when the mitochondrial membrane potential is high
and the ADP levels are low, the production of ROS is high. In
state 3, when the membrane potential is low and the ADP
concentration is high, the production of ROS is low. Another
source of ROS is the production of H2O2 by monoamine
oxidase in mitochondria, the various flavin oxidases in
peroxisomes and the leakage of electrons from cytochrome
P-450 in the endoplasmic reticulum (ER) [32–34].
The free radicals formed in the cell are able to damage
lipids, proteins and DNA, a concept known as oxidative
stress. Lipid peroxidation is by far the most studied process
and the initiation occurs by abstraction of a hydrogen atom
from a methylene group of a polyunsaturated fatty acid
(PUFA). The results of lipid peroxidation are carbon-centered
free radical, peroxyl radical, lipid hydroperoxide, alkoxyl
radical and degradation to hydrocarbons, alcohols, ethers,
epoxides and aldehydes. The aldehydes formed are relatively
long-lived and can therefore diffuse a longer distance from
their site of origin than free radicals. Since they can also react
with macromolecules, they further contribute to the damage
caused by lipid peroxidation. A secondary defense mecha-
nism involving phospholipase A2 removes the peroxidized
fatty acid that can be replaced by new fatty acids [35]. If the
removed fatty acid is not replaced completely, the lysophos-
pholipid formed acts as a detergent and damages the mem-
brane. Other defense systems are the glutathione peroxidases,
especially the phosphohydrolipid glutathione peroxidase,
that scavenge the lipid hydroperoxides formed during lipid
peroxidation [36].
Protein oxidation usually occurs at certain amino acid
residues of a particular protein. Although some amino acids
are more prone to oxidation than others, the selectivity of
the initiating attack is attributed to protein-bound transition
metals that react with ‘‘weak ROS’’ and form hydroxyl
radicals at the metal-binding site [37,38]. The subsequent
abstraction of a hydrogen atom and formation of peroxyl
radicals and hydroperoxides are similar to lipid peroxida-
tion. Propagation can occur within the protein, to another
protein or to lipids. Oxidation of membrane proteins can
also take place by lipid-derived free radicals [39]. Oxidized
proteins are recognized by specific proteases and completely
degraded to amino acids. Thus, replacement by de novo
synthesis of proteins is the only repair mechanism [40,41].
DNA oxidation by ROS is believed to be dependent on
transition metals in a similar manner to protein oxidation
[42]. Due to the relatively high production of ROS in
mitochondria, lack of protective histones and limited ability
of repair, mitochondrial DNA has about 10-fold higher
oxidative damage than nuclear DNA [43]. Oxidized DNAis repaired by two enzymatic mechanisms, removal and
subsequent replacement of single oxidized deoxyribonu-
cleotides and/or excision of 25–32 nucleotides long
oligomers of oxidized bases that are replaced by DNA
polymerase and subsequently sealed by DNA ligase [44].
Antioxidants are enzymes and nonenzymatic agents that
can prevent the formation of, or remove ROS. Antioxidant
enzymes include superoxide dismutase and various perox-
idases such as glutathione peroxidase, catalase, thioredoxin
reductase and peroxiredoxin [45,46]. Nonenzymatic agents
include vitamins C and E, carotenoids, glutathione, a-lipoic
acid, flavinoids and the reduced form of CoQ (CoQH2) that
all rely on a mechanism of regeneration in the cell.
CoQH2 was originally described to inhibit lipid perox-
idation in vitro using submitochondrial particles [47,48]. It
is now well established that CoQH2 is able to prevent lipid
peroxidation in most subcellular membranes [49]. The lipid
plays an important role as antioxidant also in the circulation
[50,51]. Since CoQH2 is oxidized during lipid peroxidation,
reductive regeneration is a requirement for participation in
antioxidative reactions. Mitochondrial CoQH2 is efficiently
regenerated by the respiratory chain and is normally kept in
a highly reduced state [52]. As it will be discussed later
(Section 7), the cell has effective systems to reduce CoQ at
all intracellular locations. Studies performed on the mech-
anism of its action suggest that CoQH2 acts by affecting the
initiation process and preventing the formation of lipid
peroxyl radicals (LOO) while vitamin E acts by quenching
these radicals (Fig. 2) [53]. It appears that CoQH2 reduces
the initiating perferryl radical with the formation of ubise-
miquinone and H2O2. It is also possible that it eliminates
LOO directly; furthermore, it is established that CoQH2
regenerates vitamin E from the a-tocopheroxyl radical. This
appears to be favored in comparison with the alternative,
which is regeneration by ascorbate. Lipid solubility, effi-
cient continuous regeneration and involvement both in the
initiation and propagation steps of lipid peroxidation explain
why CoQ is considered as a highly efficient antioxidant
against radicals produced in biological membranes. In fact,
it appears that this antioxidant is considerably more efficient
than vitamin E [54].
When phosphatidylcholine liposomes are oxidized with a
water-soluble radical initiator in the presence of ascorbate,
a-tocopherol (a-T) and CoQ the antioxidants are consumed
in the order: ascorbate–CoQ–a-T [55]. When a lipid-
soluble radical initiator is used, the antioxidants are con-
sumed in the order: CoQ–ascorbate–a-T. Thus, a-T is
efficiently spared in both cases and this kinetic data showed
that the a-tocopheroxyl radical formed is reduced by
CoQH2. This sparing effect of a-T by CoQH2 has also
been observed in low density lipoprotein (LDL) [56,57].
The fact that the antioxidant function of CoQH2 is not
dependent on the presence of a-T, is evident from the fact
that submitochondrial particles containing CoQ are pro-
tected from lipid peroxidation also in the absence of a-T
[58].
 Fig. 3. Proposed role of coenzyme Q in UCP function. A proton (H+) is
delivered from a fatty acid (FA-CO2H) to the UCP with the assistance of
CoQ in the inner mitochondrial membrane. The UCP subsequently
translocates the proton to the matrix. The figure is based on the proposals
from Echtay et al. [71].
Fig. 2. Sites of action of CoQ, vitamin E and ascorbate on lipid
peroxidation. Abbreviations: LH, polyunsaturated fatty acid; OH, hydroxyl
radical; Fe3+O2
, perferryl radical; CoQH2, reduced coenzyme Q; CoQH
,
semiubiquinone; L, carbon-centered fatty acid radical; LOO, lipid peroxyl
radical; VitE-OH, vitamin E (a-tocopherol); VitE-O, a-tocopheroxyl
radical; Asc, ascorbate; Asc, ascorbyl radical; LOOH, lipid hydroperoxide;
LipDH, lipoamide dehydrogenase; TrxR, thioredoxin reductase; GR,
glutathione reductase.
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by CoQH2 [39,59,60]. DNA oxidation measured by 8-
hydroxydeoxyguanosine formation in rat liver mitochondria
and DNA strand breaks in human lymphocytes is also
prevented by CoQH2 administration both in vitro and in
vivo [49,61,62]. Finally, reduced plastoquinone found in
plant chloroplast membranes exerts an antioxidant activity
similar to that shown for CoQH2 [63].
1.3. Uncoupling proteins (UCPs)
UCPs are situated in the inner mitochondrial membrane
and can translocate H+ from the outside to the inside of the
mitochondria. Thus, the proton gradient built by the respi-
ratory chain is uncoupled from oxidative phosphorylation
and heat rather than energy is produced [64–66]. UCPs
occur in many animal and plant cells and form a subfamily
of the mitochondrial carrier family. Five UCPs (1–5 in
humans) are known and UCP1 is the most well character-
ized, present in brown adipose tissue where it participates in
thermogenesis [67,68]. In other tissues where uncoupling is
not a dominant feature, UCPs occur only in small amounts.
UCP2 is expressed in most animal tissues and UCP3 is
expressed most abundantly in human skeletal muscle [69].
In addition to thermogenesis, UCPs could be involved in
suppression of oxygen radicals. There are also suggestions
that altered UCP expression could be related to human
diseases, such as obesity and diabetes.Recently Echtay et al. [70,71] showed that CoQ is an
obligatory cofactor for UCP function using bacterial over-
expressed UCP1, -2 and -3 in liposomes. These liposomes
were unable to transport H+ in the absence of CoQ and H+
transport was activated when CoQ was added to the mem-
branes in the presence of fatty acids. The CoQ-stimulated
activity could be inhibited by addition of ATP. Full activa-
tion of UCPs in reconstituted vesicles was achieved with
CoQ/phospholipid ratio of 1:300 and CoQ/UCP ratio of
80:1. It was proposed that CoQ interact with UCP in the
hydrophobic bilayer since maximal activity was achieved
with CoQ10 and hydrophilic CoQs with none or a short
isoprenoid side chain (0–2 isoprenes) were ineffective to
activate UCPs (Fig. 3) [71]. It was also suggested that the
interaction between CoQ and UCP3 occurred closer to the
membrane surface, since UCP3 retains some of its activity
with hydrophilic CoQs. Thus, CoQ, but not ubiquinol, could
in an active way subtract H+ from fatty acids and deliver
them to the H+ acceptor group of the UCP. Consequently,
the oxidized form of CoQ has to be present in mitochondria
for this activation.
1.4. The mitochondrial permeability transition pore (PTP)
The inner membrane of the mitochondria has a low
permeability to ions and solutes in order to permit energy
conservation in the form of an electron and a pH gradient
over the membrane. In order to facilitate trans-membraneous
transport, the inner membrane contains a number of mac-
romolecule transporters and ion channels. However, under
in vitro accumulation of Ca2+, the mitochondria can undergo
a generalized increase of permeability of the inner mem-
brane, known as permeability transition. This enable macro-
molecules with a size of approximately 1500 Da to cross the
membrane causing collapse of the protonmotive force,
Table 2
Effects on human monocytes after coenzyme Q supplementation
10-week CoQ treatment
(% of 0 week)
CoQ
Plasma 218
Mononuclear cells 149
Polynuclear cells 101
a-Tocopherol
Plasma 108
Mononuclear cells 201
Polynuclear cells 158
Arachidonic acid in phospholipids
Mononuclear cells 134
CD11b, mononuclear cells
Resting 27
Stimulated 58
CD35, mononuclear cells
Resting 38
Stimulated 79
Data taken from Turunen et al. [88].
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hydrolysis of ATP [72]. The permeabilization of the mem-
brane is due to the opening of an inner mitochondrial
complex, the PTP. The PTP behaves like a voltage-depen-
dent channel, favoring a closed conformation at high mem-
brane potentials and an open conformation at low membrane
potentials. Upon Ca2+ accumulation, more than 40 classes
of unrelated factors can modulate the PTP to open or close,
including the mitochondrial membrane potential, the matrix
pH, cyclosporin A, phosphate, oxidized glutathione and
pyridine nucleotides derived from oxidative stress. The
permeability transition has been proposed to be an early
key event in several models of apoptosis causing activation
of the caspase cascade through release of cytochrome c [73].
Under physiological conditions, it is thought that the PTP
serves as a fast Ca2+ release channel in the mitochondria
[74,75].
Several analogues of CoQ have been shown to affect the
PTP [76–78]. They all contain a benzoquinone ring with
either none or a short (0–2 isoprenes) saturated or unsatu-
rated side chain and can be divided into three functional
classes; inhibitors, inducers and inactive quinones that
counteract the effects of both the inhibitors and the inducers.
The structure–function correlation of these analogues has
suggested that minor changes in the isoprenoid side chain
can turn an inhibitor into an inducer and that the methoxy
groups are not essential for activity [77]. It has therefore
been suggested that quinones modulate the PTP through a
common binding site rather than through redox reactions.
CoQ10 seems also to prevent PTP opening, since it was
shown in a recent study that CoQ10 is able to counteract
mitochondrial membrane potential depolarization, ATP de-
pletion, cytochrome c release, caspase-9 activation and
DNA fragmentation in keratinocytes upon apoptotic stimuli
[79]. However, the actual PTP opening and the mechanism
of action by CoQ10 were not investigated in this study.
1.5. Lymphocytes and monocytes
Isolated human blood lymphocytes increase their CoQ10
content several folds upon incubation with liposomes con-
taining CoQ10 [61]. Supplementation of human subjects
with 300 mg/day CoQ10 for 1 week elevates the lipid
content in lymphocytes from 14 to 32 pmol/106 cells [62].
In vitro supplementation was proved to enhance DNA
resistance for hydrogen peroxide-induced oxidation but it
did not inhibit DNA strand break formation [61]. The in
vivo enrichment of CoQ10 in lymphocytes was shown to
inhibit oxidative DNA damage and enhanced the DNA
repair enzyme activity in these lymphocytes [62]. Two
months of CoQ10 administration to humans appears to
affect the qualitative distribution of cells by increasing the
ratio of T4/T8 lymphocytes in a significant extent [80,81].
An increase in the number of lymphocytes was also ob-
served in a study after 3 months of dietary CoQ10 supple-
mentation in humans [82]. An investigation of a healthypopulation in ages 90–106 years indicated that in women
NK cell cytotoxicity is positively associated with plasma
CoQ10 concentration [83].
Blood components are considered to play an important
role during development of atherosclerosis. Monocytes
initially attach and accumulate on the endothelial cells
which are covering the arterial wall and appear as macro-
phages after migration [84,85]. According to this concept,
the accumulation of oxidized cholesterol in macrophages is
the main reason for the development of the atherosclerotic
plaque. The process of monocyte–endothelial interaction is
mediated by several substances and cellular components.
One of the main factors is the adhesion molecules, the
integrins, which upon stimulation are recruited to the
surface of the cell [86,87]. Administration of CoQ10 to
humans results in an uptake into monocytes but not into
granulocytes (Table 2) [88]. Interestingly, a-T content is
elevated in both monocytes and granulocytes. The phos-
pholipid fatty acid composition displays a very selective
modification, appearing as an increase of the arachidonic
acid content. When the basal and stimulated levels of h2-
integrin CD11b and complement receptor CD35 were in-
vestigated, the expression of these receptors on the cell
surface was found to be decreased considerably. Again,
these changes were restricted only to monocytes. The anti-
atherogenic effect of CoQ10 was established earlier from
studies on apolipoprotein E deficient mice fed a high fat diet
[89,90]. It was shown in these investigations that upon CoQ
administration, in addition to the increased aortic CoQ and
a-T levels and the decreased concentration of hydroperox-
ides in the atherosclerotic lesions, there was a clear decrease
of lesion size in the whole aorta. This could not be attributed
solely to an antioxidative effect since several oxidative
stress markers did not decrease in this study. The decrease
of adhesion factors upon dietary CoQ administration
appears to inhibit the recruitment of monocytes to the
Table 4
Coenzyme Q, dolichol, cholesterol and a-tocopherol in subcellular
organelles of rat liver
Organelle CoQ Dol+Dol-P
(Ag/mg
protein)
Cholesterol a-Tocopherol
Nuclear envelope 0.2 0.2 37.5 0.01
Mitochondria 1.4 0.09 2.3 0.04
Outer membranes 2.2 0.25 30 0.06
Inner membranes 1.9 0.009 5.0 0.04
Microsomes 0.2 0.4 28 0.07
Rough microsomes 0.2 0.5 16 0.04
Smooth microsomes 0.3 0.3 31 0.09
Lysosomes 1.9 4.7 38 0.18
Lysosomal membranes 0.4 0.6 6.1
Golgi vesicles 2.6 1.7 71 0.48
Peroxisomes 0.3 0.8 6.4 0.02
Plasma membranes 0.7 0.8 128 0.008
CoQ, coenzyme Q; Dol, dolichol; Dol-P, dolichyl phosphate. Data taken
from Lo¨w et al. [110], Zhang et al. [209] and Ericsson and Dallner [301].
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sion of the disease. Consequently, other mechanisms than
antioxidant protection only are involved in the anti-athero-
genic effect of CoQ.
1.6. Endothelial function
One of the characteristic events in many diseases, such as
diabetes and cardiovascular diseases, is endothelial dysfunc-
tion of the arteries which has serious consequences [91].
When the function of the brachial artery was measured as
flow-mediated dilatation and glyceryl-trinitrate-mediated
dilatation following dietary supplementation with CoQ10,
a sizeable improvement of endothelial function was ob-
served [92]. CoQ10 administration to type 2 diabetic
patients also lowers systolic blood pressure and HbA1c but
it does not decrease F2-isoprostanes [93]. Increased endo-
thelial release of nitric oxide is the most probable explana-
tion for the arterial effect causing dilatation.2. Distribution
2.1. Tissues
CoQ is present in all tissues and cells but, on weight
basis, in variable amounts (Table 3A). The lipid is also
found in all isolated lipoprotein fractions of human bloodTable 3
(A) Coenzyme Q amount, type and extent of reduction in human and rat
tissues
Rat Human
CoQ9 CoQ10 %
Reduced
CoQ9 CoQ10 %
Reduced
Heart 202 17 22 3 114 47
Kidney 124 22 42 3 67 73
Liver 131 21 87 2 55 95
Muscle 43 3 40 1 40 60
Brain 37 19 27 1 13 23
Pancreas 37 3 62 2 33 100
Spleen 23 9 18 1 25 87
Lung 17 2 12 1 8 24
Thyroidea 44 7 45 1 25 68
Testis 32 5 49 1 11 78
Intestine 51 19 67 1 12 93
Colon 48 8 52 1 11 83
Ventricle 56 5 52 12 59
(B) Coenzyme Q amount in different part of bovine brain
CoQ10
Temporal cortex 10
Parietal cortex 15
Hippocampus 6
Striatum 25
Medulla oblongata 5
White matter 3
The values are given in Ag/g tissue. Data taken from A˚berg et al. [52] and
Runquist et al. [96].[94]. The main species in rat is CoQ9 that varies from 17
Ag/g tissue in lung to 202 Ag/g in heart [52]. About 10–20%
of the total CoQ in rat has 10 isoprenes, CoQ10, with the
exception of brain, spleen and intestines where 30–40% of
the total is CoQ10. In human the main species is CoQ10
which ranges from 8 Ag/g in lung to 114 Ag/g in heart. Small
amounts, 2–7% of CoQ9, are also found in all human
tissues. By employing rapid extraction, partition and direct
injection of the extract into HPLC, it is possible to estimate
the degree of reduction, most probably existing also in vivo
[95,302]. This shows that the degree of the reduced state is
very high, more in human than in rat, with the exception of
lung and brain. The reducing systems in various organs, as
discussed later on, are highly efficient.
The concentration of CoQ varies greatly not only among
different organs but also among various cells and regions of
the same organ, which is exemplified by the bovine brain in
Table 3B [96]. Manifold differences are apparent between
the individual regions, indicating both structural and func-
tional specializations, e.g. histological structure and number
of mitochondria.
2.2. Intracellular distribution
All organelles isolated upon subfractionation of the liver
contain the different types of mevalonate pathway lipids,
although in most variable amounts (Table 4). The highest
amounts of CoQ (on protein basis) are found in the outer and
inner mitochondrial membranes, lysosomes and Golgi
vesicles. Dolichol is enriched in lysosomes andGolgi vesicles
while cholesterol shows the characteristic gradient: rough
microsomes!smooth microsomes!lysosomes!Golgi ves-
icles!plasma membranes. Golgi vesicles are the far most
dominant organelle concerning a-T enrichment.
In most species, one chain length of CoQ is dominating
and in a minor extent a lipid with a shorter or a longer side
chain is also found. The situation is, however, quite different
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family of polyisoprenoids with six to seven members [97]. It
was proposed that the heterogeneity of CoQ is required for
functional specializations, such as for mitochondrial respi-
ration and for antioxidative action [98]. The experiences are,
however, not in favor of such specialization. In rat brain
where one-third of the CoQ has 10 isoprene residues, the
distribution pattern is identical in various regions and also in
subcellular organelles [99]. The effectiveness to serve as
respiratory chain redox carrier or as an antioxidant agent is
not influenced by the length of the isoprenoid side chain
[100–102]. Upon reconstitution of extracted beef heart
submitochondrial particles, either with CoQ9 or CoQ10
within the physiological range of lipid concentrations, no
differences could be observed in the rate of superoxide
generation [103]. In spite of these facts, in some cases the
type of CoQ species is of importance. Activation of UCPs
and regulation of the mitochondrial PTP have selective
requirements [71,78]. It was observed that mumps virus
infection of dorsal ganglion cells, which contain both CoQ9
and CoQ10, led to a decrease of these lipids and resulted in
neuronal degeneration [104]. The cells could be rescued by
addition of CoQ10 to the culture but not by addition of
CoQ9.
2.3. Intramembranous localization
Lipids of the mevalonate pathway have distinct intra-
membranous localizations that has considerable consequen-
ces on membrane properties. Polyisoprenoid chains of
CoQ, dolichol and dolichyl-P are present in the central
hydrophobic region, between the double layers of phos-
pholipid fatty acids (Fig. 4) [105–108]. They probably
have a coiled formation and the three lipids saturate the
available space, since membrane thickness is considered to
be a characteristic of the membrane type investigated. The
functionally active groups, the benzoquinone ring of CoQ
and the phosphorylated a-isoprene of dolichol-P, turn out
to the outer or inner surface of the membrane dependingFig. 4. Intramembraneous distributionon the functional requirement. This central localization is
considered to destabilize membranes and results in an
increased fluidity and permeability. On the contrary, the
other obligatory membrane component, cholesterol, is
distributed between fatty acids on one side of the lipid
leaflet, thereby causing stabilization with decreased fluidity
and permeability [109].
This arrangement of isoprenoid-derived lipids has two
major consequences. First, all membranes have to be satu-
rated with the appropriate lipid for optimal function and the
level of saturation is dependent on the structural organiza-
tion of the membrane type. Second, if a membrane is
deficient in an isoprenoid, the consequences for membrane
function, e.g. fluidity, will be deleterious. In this case, one
can expect an uptake from exogenous sources up to the limit
of saturation. If the uptake continues, the excess lipid has to
have a non-membranous distribution. In fact, lysosomes
have a CoQ and dolichol content that exceeds several-fold
the content of other membranes. After sonication, however,
the major part of the lipid content is solubilized, including
80% of CoQ, and the lysosomal membranes exhibit a
similar concentration of polyisoprenoids as the other cellular
membranes [110]. Also, exogenous CoQ, taken up by the
liver and appearing in organelles, can to a large extent be
removed by mechanical treatment [111].
2.4. Removal of CoQ from membranes
There are limited possibilities to obtain an in vitro system
with different CoQ contents and amounts of other neutral
lipids. Extraction with selected organic solvents, preferen-
tially with n-pentane, is one of the few ways for such studies
[4]. The principle of this procedure is that membranes
prepared in sucrose-free medium are lyophilized and repeat-
edly extracted with n-pentane. Thereafter, the extracted
samples are equilibrated with n-pentane containing various
amounts of CoQ (and/or cholesterol, dolichol and a-T). After
drying the resuspended fraction, the preparation can be used
for various measurements. The great advantage for using thisof mevalonate pathway lipids.
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proteins are extracted and most of the integral membrane
enzymes are not denatured, and one can analyze enzyme and
membrane properties in the presence of different CoQ content
alone or together with other neutral lipids [112,113].3. Biosynthesis
The biosynthesis of CoQ has been extensively investi-
gated in bacteria and yeast but only studied to a limited
extent in mammals. The terminal part of the bacterial CoQ
biosynthesis differs from yeast in the order of synthetic
events, i.e. in prokaryotes the modifications of the ring after
attachment of the side chain proceeds via a decarboxylation
prior to hydroxylation and methylation whereas in eukar-
yotes decarboxylation occurs after hydroxylation and meth-
ylation. All COQ genes isolated from yeast (COQ1–8) have
a putative mitochondrial targeting signal and no isoenzymes
have been identified [114]. However, CoQ is found in all
subcellular compartments and, hence, a transport should
exist from mitochondria to other membranes. In mammalian
tissues, only two genes (COQ3 and COQ7) have been
isolated through complementary recognition with yeast
[115,116].
3.1. The mevalonate pathway
The mevalonate pathway comprises the reactions starting
from acetyl-coenzyme A (acetyl-CoA) and ending up withFig. 5. The enzymatic conversion and condensation of acetate to farnesyl-PP and
CoA, coenzyme A; DMAPP, dimethylallyl pyrophophate; FPP, farnesyl pyr
methylglutaryl; 4OH, 4-hydroxy; IPP, isopentenyl pyrophosphate. Key enzymes afarnesyl pyrophosphate (FPP), the substrate for the biosyn-
thesis of CoQ, cholesterol, dolichol and isoprenylated pro-
teins (Fig. 5) [117]. Thus, the conversion of acetyl-CoA to
FPP is common for all end-products. This organization is
unusual since the biosynthetic sequence is identical for
several lipids and one could expect that production of one
lipid greatly influences the synthesis of the other lipids.
However, the mevalonate pathway lipids are synthesized in
highly different rates and amounts, which involves, in
addition to the central regulation, a terminal regulation.
The regulatory enzymes are probably the branch-point
enzymes utilizing FPP. This fact makes the mevalonate
pathway very complex in animal cells.
The initial part of the mevalonate pathway involves the
condensation of three acetyl-CoA to 3-hydroxy-3-methyl-
glutaryl-coenzyme A (HMG-CoA), which is mediated by
two enzymes, acetoacetyl-CoA thiolase and HMG-CoA
synthase. HMG-CoA reductase then converts HMG-CoA
to mevalonate. This enzyme has been studied extensively
and is considered to be the main regulatory enzyme in
cholesterol biosynthesis [118]. Effective competitive inhib-
itors of this enzyme, compactin and mevinolin and their
derivatives, are in the western world among the most
commonly used drugs [119]. Interestingly, these inhibitors
induce the synthesis of the reductase at the transcriptional
level and, additionally, inhibit the degradation of the en-
zyme [120]. The action of inhibitors therefore leads to low
enzyme activity but high amount of enzyme. Cholesterol
mainly affects HMG-CoA reductase by feedback regulation
but the enzyme is influenced by many other mechanisms,subsequent biosynthesis of CoQ, cholesterol and dolichol. Abbreviations:
ophosphate; GGPP, geanylgeranyl pyrophosphate; HMG, 3-hydroxy-3-
re indicated in italic.
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One of the factors behind the rapid and reversible regulation
of this enzyme can be inactivation–activation elicited by
phosphorylation–dephosphorylation of the protein [123].
Mevalonate is subsequently phosphorylated in two steps
by mevalonate kinase and phosphomevalonate kinase.
Mevalonate phosphates appear, in addition to intermediates,
to be regulators of cell proliferation and DNA synthesis
[124]. Decarboxylation of mevalonate pyrophosphate yields
isopentenyl pyrophosphate (IPP), which is not only a
precursor of FPP but also the main building block in the
polyisoprenoid biosynthesis of dolichol and the side chain
of CoQ. Isomerization of IPP gives dimethylallyl pyrophos-
phate which is an intermediate in the biosynthetic process of
isoprenoid lipids and, furthermore, also participates in the
synthesis of isopentenyl tRNAser/sec at the position six of an
adenosine (i6A) [125,126]. This isoprenylation of tRNAser/
sec is necessary for an effective selenoprotein synthesis.
Farnesyl pyrophosphate synthase utilizes IPP and its
isomer dimethylallyl pyrophophate to make FPP with the
formation of an intermediary product, geranyl pyrophos-
phate (GPP) [127]. This model involves GPP’s presence
only as an enzyme-bound intermediate. On the other hand, it
was previously found that GPP—at least in in vitro con-
ditions—is serving as the main precursor in solanesylTable 5
Isolated genes encoding the enzymes involved in the terminal biosynthesis of co
Enzyme Gene
trans-Prenyltransferase COQ1
DSP
ISPB
Polyprenyl-4-hydroxybenzoatetransferase COQ2
PPT1
UBIA
Monooxygenase UBIB
Unknown function COQ4
2,3-Dihydroxy-5-polyprenylbenzoate-methyltransferase COQ3
UBIG
Unknown function ABC1
Decarboxylase UBID
UBIX
C-Hydroxylase COQ6
UBIH
C-Methyltransferase COQ5
UBIE
3-Methoxy-6-methyl-5-polyprenyl-benzoquinone-hydroxylase COQ7
UBIF
CLK-1
Coq1-8p COQ1pyrophosphate and decaprenyl pyrophosphate synthesis
both in rat liver and spinach homogenates [128,129]. If
the major substrate for trans-prenyltransferase is GPP also
in vivo, it should be a GPP pool for this purpose. Direct
measurements of possible pools concerning mevalonate,
FPP and GPP are, however, not yet made and therefore this
question is unanswered. During various experimental con-
ditions like fasting, cholesterol feeding, treatment with
cholestyramine or mevinolin, FPP synthase is influenced
in coordination with HMG-CoA synthase and HMG-CoA
reductase activities [130]. The major part of hepatic FPP
synthase is present in the cytoplasm but some activity is
found in all organelles isolated [117]. The enzymatic activ-
ity at different locations exhibits different responses upon
treatment of rats with inducers and drugs, which demon-
strate that the enzyme is subjected to separate regulation
depending on its location in cytosol, microsomes, mitochon-
dria or peroxisomes [131].
The next enzymes in the biosynthesis of cholesterol,
dolichol, CoQ and protein isoprenylation, i.e. squalene
synthase, cis-prenyltransferase, trans-prenyltransferase and
farnesyl-protein transferase, are considered to be the rate-
limiting enzymes in the terminal part of their biosynthetic
process. The isoprenoid biosynthetic enzymes in the meval-
onate pathway are evolutionarily closely related. X-rayenzyme Q
Isolated or cloned from Reference
Saccharomyces cerevisiae [305]
Schizosaccharomyces pombe [306]
Escherichia coli [307]
Saccharomyces cerevisiae [140]
Schizosaccharomyces pombe [308]
Escherichia coli [309]
Escherichia coli [167]
Saccharomyces cerevisiae [114]
Saccharomyces cerevisiae [149]
Mouse [154]
Rat [153]
Human [115]
Escherichia coli [150]
/COQ8 Saccharomyces cerevisiae [310]
[166]
Escherichia coli [311]
Escherichia coli [312]
Saccharomyces cerevisiae [165]
Escherichia coli [313]
Saccharomyces cerevisiae [314]
Escherichia coli [315]
/CAT5 Saccharomyces cerevisiae [157]
[158]
Mouse and Rat [160]
Escherichia coli [316]
/COQ7 Caenorhabditis elegans [161]
Mouse [159]
Human [163]
[116]
–8 Caenorhabditis elegans [184]
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derivatives as substrate have 3D structures similar to the
avian FPP synthase [132].
3.2. The terminal part of CoQ biosynthesis
Although the genes in the terminal part of the CoQ
biosynthesis have been cloned in bacteria and to some
extent in yeast, there is still a limited amount of information
about the biosynthetic enzymes in mammalian tissues. The
genes so far identified as encoding the enzymes in CoQ
synthesis are given in Table 5.
3.2.1. trans-Prenyltransferase, Coq1p
The trans-prenyltransferase catalyzes the condensation of
FPP with several IPPs, all in trans configuration, to form a
long isoprenoid chain. The enzyme belongs to class III
enzymes in the trans-prenyltransferase family. While class I
enzymes produce short isoprenoid chains and class II
produces medium and long chains, class III only produces
long isoprenoid chains. Although the short chain enzymes
(e.g. FPP synthase) have been thoroughly characterized, the
class III enzymes are still elusive. Only a few enzymes have
been isolated, all in bacteria and yeast, and their character-
ization is based on complementary rescue of null mutants
[133]. Most of them form homodimers and all require Mg2+
for activity. All classes share several conserved aspartic
acid-rich sequence motifs and the length of the side-chain
produced is species-specific. For instance, Saccharomyces
cerevisiae make CoQ6, E. coli synthesizes CoQ8 and
rodents and humans produce mainly CoQ9 and CoQ10,
respectively. This specificity is retained within the gene
sequence, since cross-expression of genes has shown thatFig. 6. Terminal reactions in the biosynthesis of Cthe length of the side chain is altered when a different trans-
prenyltransferase encoding gene is expressed [134]. It is
believed that Mg2+ serves to bind the substrate and that the
region located around the first aspartic acid-rich motif
regulates the length of the side chain produced. Especially
the fifth amino acid, upstream the first aspartic acid-rich
motif, seems to be important. If this amino acid is changed
from alanine to an aromatic amino acid, the polyisoprenoid
produced is shifted from a long chain to geranylgeranyl
pyrophosphate [132]. The reverse has also been shown
using FPP synthase and geranylgeranyl pyrophosphate syn-
thase [135,136].
While the yeast trans-prenyltransferase is considered to
be a mitochondrial protein, mammalian trans-prenyltrans-
ferase activity is mostly found in the ER, while lower
activities are found in the mitochondria, Golgi vesicles
and peroxisomes [128]. The rat trans-prenyltransferase also
has a requirement for divalent cations but prefers trans-GPP
and IPP as substrates. In vitro measurements of the rat and
mouse trans-prenyltransferase have shown that the activity
can be induced by administration of peroxisomal inducers
[128,137].
3.2.2. Polyprenyl-4-hydroxybenzoate transferase, Coq2p
In the terminal part of CoQ synthesis two substrates are
required, polyprenyl pyrophosphate and the ring structure,
4-hydroxybenzoate (Fig. 6). This latter substrate originates
from tyrosine but theoretically it may also be deduced from
phenylalanine either by hydroxylation to tyrosine or by
enzymatic transformation similar to that of the tyrosine
molecule. The intermediates given in Fig. 5 are produced
by the action of transaminase, dehydrogenase, dehydratase
and completed by a h-oxidation. It was found that this h-oQ. PPHB: polyprenyl-4-hydroxybenzoate.
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peroxisomal oxidation, but the localization of biosynthesis
is not analyzed in detail [138]. Since tyrosine is an essential
amino acid in animal cells, contrary to bacteria and yeast,
availability of the ring could be rate-limiting in an in vivo
system. The experience is, however, that this substrate is in
excess in tissues and the fact that 4-hydroxybenzoate is in
10-fold excess in the urine compared to the daily need for
CoQ biosynthesis also supports this assumption [139]. Since
4-hydroxybenzoate is a common bacterial product in the
intestinal system of animal organisms, it is possible that this
supply is far exceeding that of endogenous production. The
second step in the terminal part of CoQ biosynthesis is
the condensation of the polyisoprenoid side-chain with 4-
hydroxybenzoate (Figs. 5 and 6). The gene encoding
polyprenyl-4-hydroxybenzoate transferase (COQ2) is
cloned and characterized in yeast and E. coli (UBIA),
but the mammalian COQ2 homologue has not yet been
identified. The predicted amino acid sequence of the yeast
and E. coli gene exhibits two conserved aspartic rich
motifs, which are believed to bind polyprenyl pyrophos-
phate [140,141]. The yeast COQ2 contains a typical N-
terminal mitochondrial leader sequence but the microsom-
al enzyme activity is nearly as high as the mitochondrial
activity and both of these activities are absent in the coq2
mutant [140]. The UBIA gene has been overexpressed and
characterized in E. coli, giving a 3000-fold enrichment in
activity [141]. The enzyme was not solubilized by hyper-
tonic buffer or detergent and was shown to be Mg2+-
dependent. A broad spectrum of isoprenoids (GPP, FPP
and solanesyl-PP) was accepted as substrates by this
enzyme. The transferase can be inhibited in vitro by
benzoate ring analogues such as 4-aminobenzoate and
4-chlorobenzoate, however, these inhibitors are not oper-
ating in vivo [142]. In cell culture, 4-aminobenzoate is
competing for solanesyl-PP and is condensated with the
polyprenol while no direct interaction is occurring with 4-
chlorobenzoate. It appears that -SH groups are essential
for the transferase activity since 4-hydroxymercuriben-
zoate is inhibitory. In vitro activity of the rat enzyme is
found in the Golgi vesicles, but also in the ER, mito-
chondria and peroxisomes [112,137,143–145,177]. The
enzymatic activity can be up-regulated by administration
of the peroxisomal inducer clofibrate [137].
There are alternative possibilities to 4-hydroxyben-
zoate as acceptor of the polyisoprenoid side chain
(Fig. 7). One of the proposals is that like fatty acids,
the ring has to be activated with coenzyme A in order
to interact with the side chain [146]. Modifications of
the ring which are considered as subsequent reactions
(hydroxylation and methylation) may precede the con-
densation reaction [138,144]. An interesting possibility is
that products of the catecholamine metabolism, proto-
catechuic and vanillic acid, which are substituted derivatives
of the 4-hydroxybenzoate, are qualified for completion to
CoQ.3.2.3. 2,3-Dihydroxy-5-polyprenylbenzoate-methyltransfer-
ase, Coq3p
There are two O-methylations in the production of CoQ
and the same enzyme presumably catalyzes both (Fig. 6). In
eukaryotes, the first O-methylation occurs after polyprenyl-
4-hydroxybenzoate has been hydroxylated. However, it has
been suggested by Kang et al. [147] that the decarboxylation
actually occurs before the first hydroxylation and methyla-
tion in rodents. The enzyme was first partially purified and
characterized in yeast and it was concluded that S-adeno-
sylmethionine (SAM) was the methyl donor [138]. Tzagoloff
and Dieckmann isolated nine separate complementation
groups in yeast containing reduced levels of CoQ, which
led to the identification of COQ3 in yeast and UBIG in E.
coli [148–150]. The predicted amino acid sequence for the
proteins of COQ3 and UBIG contains four sequence motifs
that are conserved in a large family of enzymes utilizing
SAM as methyl donor [151,152]. The rat COQ3 cDNAwas
recovered by its ability to rescue CoQ biosynthesis in yeast
coq3 mutants [153]. Its N-terminus shares the features
common for mitochondrial import sequences. The rat cDNA
has then been used to map the mouse COQ3 to the proximal
region of chromosome 4 and for the identification of the full-
length human cDNA [115,154]. Using farnesylated ana-
logues, 2,3-dihydroxy-5-polyprenyl-1,4-benzoic acid and
demethylubiquinone, together with radiolabeled SAM, it
was concluded that the same enzyme could possibly perform
bothO-methylations and that Coq3p or UbiGp is required for
in vitro activity in yeast and E. coli [155,156]. The activity of
Coq3p was found in yeast mitochondria and cell-free
extracts of E. coli. Using [3H]SAM, we have also found an
in vitro methylation activity of the farnesylated analogues
(supplied by C.F. Clarke, UCLA) in rat liver microsomes and
mitochondria. However, the major part of the activity was
recovered from the cytosol and therefore it is unclear to what
extent the cytosolic catechol-O-methyltransferase contrib-
utes to these activities. Catechol-O-methyltransferase shares
several features with the Coq3p, since they are both depen-
dent on a divalent cation and utilize SAM. Their amino acid
Fig. 7. Possible ring acceptors in CoQ biosynthesis.
M. Turunen et al. / Biochimica et Biophysica Acta 1660 (2004) 171–199182sequences, however, fail to show any homology with yeast
COQ3 outside the sequence motifs for SAM binding that are
conserved for all SAM-dependent enzymes.
3.2.4. 3-Methoxy-6-methyl-5-polyprenyl-benzoquinone-hy-
droxylase, Coq7p
The second out of two mammalian genes identified in the
terminal part of the CoQ biosynthesis is COQ7 [116]. The
enzyme hydroxylates 3-methoxy-6-methyl-5-polyprenyl-
benzoquinone (demethoxy-ubiquinone) yielding 2-hydrox-
yubiquinone [157]. The yeast gene was independently
isolated as CAT5, and was thought to be encoding a protein
required for release of gluconeogenic genes from glucose
repression [158]. Later studies, however, showed that this
gene is directly involved in CoQ biosynthesis and that the
defect in gluconeogenetic gene activation could be restored
by CoQ supplementation [159]. CoQ biosynthesis in S.
cerevisiae coq7 null mutants could be restored with the
complementary COQ7 genes from rat, humans or the CLK-1
gene from C. elegans [116,160,161]. The clk-1 mutants
show early developmental arrest and sterility, and this
phenotype can be rescued by a dietary source of CoQ
[162]. The mouse clk-1 mutant accumulates demethoxy-
ubiquinone in heart and liver mitochondria. This product is
redox active and can partially compensate for some of the
defective respiratory functions seen in C. elegans clk-1
mutants [163]. It appears, however, to lack capacity as
antioxidant. The CLK-1 is a gene determining the life span
and was found to be conserved among eukaryotes, such as
yeast, rodents and humans [161,164]. Consequently, the
interest for this gene is accentuated and the fact that the
CLK-1 homologue COQ7 is participating in CoQ biosyn-
thesis gives great possibilities for hypotheses concerning
connections between life span and CoQ metabolism.
In a recent study using RNA inteference, eight genes of
CoQ synthesis (COQ1–8) were identified in C. elegans
[184]. It was demonstrated that not only CLK-1 but all the
other genes are of importance for life span in C. elegans.
In silencing experiments of the individual genes, there
were unchanged mitochondrial respiratory activities but
superoxide production was decreased and life span were
extended.
3.2.5. Other CoQ biosynthetic enzymes
There are eight modifications of the benzoate ring and
only two mammalian genes are isolated and their enzymes
partly characterized [115,116]. Coq3p catalyzes two O-
methylations and coq7p catalyzes one hydroxylation. Out
of the remaining five reactions (C-methylation, decarboxyl-
ation and three hydroxylations) only some have been
characterized in yeast and bacteria. The COQ5 gene has
been attributed to the C-methylation of the ring and the
COQ6 gene is suggested to be involved in one of the
hydroxylations [165,311]. COQ4 and ABC1/COQ8 have
been isolated although their function is unknown
[114,166]. The UBIB gene of E. coli was recently identifiedand proposed to be involved in the first monooxygenase
step [167]. Although the genes are now identified, much of
the work on the biosynthesis of CoQ is still inconclusive
and further work on a protein level is needed before the
COQ genes can truly be attributed to the individual steps in
CoQ biosynthesis. Identification and characterization of the
individual steps, however, may turn out to be more difficult
than it appears at present. The studies of Hsu et al. [168]
have established that the major sequence of CoQ synthe-
sizing enzymes, products of COQ3–COQ8, is organized in
a multi-subunit complex in yeast. Consequently, the indi-
vidual coq null mutants do not necessarily produce the
appropriate intermediate which can be used both for iden-
tification and as substrates in enzymatic studies, since the
presence of all polypeptides may be required for the proper
function and stability of the complex. In fact, the different
yeast coq mutants (coq3–coq8) fail to produce CoQ and all
of them accumulate mainly or exclusively 3-hexaprenyl-4-
hydroxybenzoic acid. This compound is the product of the
protein controlled by the COQ2 gene, which parallels the
Coq1p by not participating in the complex. It appears
probable that in animal tissues the organization of the
biosynthetic system is similar, since both isolated perfused
beating rat heart and mitochondria prepared from rat heart
accumulate nonaprenyl- and decaprenyl-4-hydroxybenzoate
[169,170].4. Intracellular transport
Independently of the locations of CoQ synthesis, the
lipid has to be transported within the cell since all cellular
membranes contain CoQ. In animal cells the mitochondrial
inner membrane, but not necessarily the outer membrane,
probably receives all of its CoQ from the synthetic machin-
ery located in the matrix–inner membrane space [138].
Liver perfusion studies established that VLDL assembled
in the ER–Golgi system contain newly synthesized CoQ
[171]. It is known that all components of the lipoprotein
have to be synthesized at the location of the assembly.
Newly synthesized CoQ is part of the lipoprotein, necessary
for antioxidant protection. The way of transport of the lipid
from the ER–Golgi system to other cellular compartments
is not established. For lipid transport in general, three
mechanisms are described: vesicular transport, carrier pro-
tein-bound transport and transport involving micellar for-
mation, all of which are possible transport ways also for
CoQ [172]. Using in vivo labeling and cell fractionation, it
was found that in spinach leaves CoQ is transported from
the ER to other compartments through a vesicle-mediated
process, which involves the Golgi system [173]. Monensin
and brefeldin are perturbing the Golgi system, resulting in
an accumulation of the lipid in the ER. In this system the
transport of CoQ is ATP-dependent but the cytoskeletal
network is not involved. Similar conclusions were attained
by applying a reconstituted cell-free system using mem-
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[174].
Transport also occurs in the opposite direction since
exogenous CoQ is translocated through the plasma mem-
brane and further intracellular transport again requires an
appropriate mechanism. After administration of exogenous
[3H]CoQ to rats, followed by subcellular fractionation, the
lipid was recovered from transport vesicles found in the
fatty layer and from possible carrier proteins in the cytosol
[111]. Recently, a new system was described which may be
of great help in studying the transport mechanism. CoQ is
absent in the electron transport chain of some yeast mutants
which, however, are able to take up external CoQ into the
plasma membrane and subsequently transport it into mito-
chondria [175]. In this way it is possible to reconstitute the
deficient electron transport chain. In some other mutant
strains the exogenous CoQ remains in the plasma membrane
since there is a defect in the transport mechanism and the
lipid is not delivered to mitochondria. Using this approach,
yeast mutants may be useful for detection and characteriza-
tion of specific transport vesicles in the cytoplasm as this
mechanism probably is involved in the translocation process
in other species.5. Compartmentalization of the mevalonate pathway
It is common that a single biological process or enzy-
matic sequence has several locations in the animal cell
contrary to one-cell organisms where functions are often
concentrated to a single membrane system. The mevalonate
pathway in rat liver is a good example for the complexity of
cellular organization (Fig. 8). Acetyl-CoA is the initial
substrate for the product which is FPP. The major part of
enzymes mediating the reactions of the pathway is presentFig. 8. Compartmentalization of the mevalonate pathway and associated reactions a
FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate; GPP, geranyin the cytoplasm with the exception of HMG-CoA reductase
which is located in microsomes and peroxisomes. However,
FPP synthase is present also at other compartments than in
the cytosol. Both mitochondria and peroxisomes can utilize
IPP for FPP synthesis, which means that both organelles
contain the isomerase and FPP synthase. Since several
enzymes of the mevalonate pathway are found in perox-
isomes, it is also possible that peroxisomes contain the
complete pathway in spite of the fact that earlier substrates
than IPP cannot be used for FPP synthesis under in vitro
conditions. Microsomal synthesis of the isoprenoid side-
chain of CoQ requires GPP rather than FPP as substrate in
both plants and rat liver, which is not explained so far, since
FPP synthase mediates a two-step reaction from dimethy-
lallyl pyrophophate and GPP is supposed to be present only
as an enzyme-bound intermediate. It is possible that some of
the terminal reactions distributed in various subcellular
organelles of rat liver require FPP to be synthesized in the
organelles themselves in order to be utilized by the branch-
point enzymes of the same organelle. An alternative possi-
bility is that a part of the synthase has structural association
with the appropriate membrane by hydrophobic or charge
forces and FPP is directly channeled into the membrane
without releasing the product, to serve FPP requiring
reactions.
CoQ biosynthesis is studied in mitochondria and in the
ER –Golgi system of both liver and spinach leaf
[129,138,145,176]. Recently, trans-prenyltransferase and
nonaprenyl-4-hydroxybenzoate transferase were also found
in peroxisomes [177] and continued studies are required to
establish the presence of other CoQ biosynthetic enzymes in
this organelle. The presence of CoQ synthesis at several
locations in animal tissues is not surprising, since other
mevalonate end products are also produced at several
locations. Cholesterol and dolichol are synthesized in bothfter the branch-point. Abbreviations: CoA, coenzyme A; CoQ, coenzyme Q;
l pyrophosphate; IPP, isopentenyl pyrophosphate.
Fig. 9. Possible functional pools in mitochondria.
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takes place in mitochondria and microsomes, in addition to
cytosol [178–180].
In general, the synthesis in two organelles does not mean
a simple doubling of the reactions but is rather related to a
specialization. h-Oxidation of fatty acids in mitochondria
and peroxisomes are utilizing different substrates and the
two organelles are cooperating in the total oxidation [181].
Mitochondria are probably producing CoQ for the respira-
tory chain and for other mitochondrial functions. On the
other hand, mitochondria cannot deliver CoQ for blood
lipoproteins and newly synthesized VLDL, during the
transport from the ER–Golgi system to the blood, has to
acquire this lipid from local synthesis. Also, ER–Golgi
CoQ is the most reasonable source of this lipid in other
cellular membranes, including plasma membranes, since
transport mechanisms from this system to other membrane
compartments are well established.
CoQ is present in various amounts in different cellular
organelles, reflecting a compartmentalization. In fact, the
function of this lipid in mitochondria, plasma membrane
and in microsomes is certainly different. Another type of
specific distribution is that of lysosomes, i.e. the presence of
the lipid in both the membrane and the vesicle lumen [110].
This luminal CoQ is not necessarily a storage compartment, it
may exert functional effects. The possibility that the lipid is
compartmentalized also within the membrane is raised re-
peatedly [182,183]. In the mitochondrial inner membrane
CoQ has at least four different functions, redox carrier,
activating UCPs, PTP regulation and antioxidant, which
makes it improbable that only one common pool is operating
(Fig. 9). UCP requires an association with oxidized CoQ10
for activation which hardly allows this pool to cooperate with
either those portions participating in the respiratory chain or
with those acting as antioxidant [70]. The fact that the
decrease of the CoQ content by 60–70% in C. elegans does
not effect CoQ-dependent mitochondrial electron transport is
also supporting the concept of compartmentalization [184]. It
would be of great interest to study also other CoQ-dependent
mitochondrial functions in this system.6. Regulation of the mevalonate pathway
The main regulatory enzyme of the mevalonate pathway
is HMG-CoA reductase, preferentially affecting cholesterolsynthesis. This is according to the classical flow diversion
hypothesis, in which the size of the FPP pool mainly
influences cholesterol synthesis [185]. Squalene synthase
has a high Km for its substrate, FPP, and already a limited
decrease in concentration leads to insufficient saturation of
the enzyme and thereby reduction of cholesterol synthesis.
Since the Km for the other branch point enzymes, cis- and
trans-prenyltransferases and farnesyl-protein transferase, are
lower, these enzymes are saturated even at lower substrate
concentrations. This kinetic arrangement is the basis for the
use of our most common drug, statins, inhibitors of the
HMG-CoA reductase. However, we do not know the actual
Km for the various enzymes, with the exception of farnesyl-
protein transferase [186], since not all of them are isolated
and no values are available for direct comparison. Most
probably, the differences in Km are not as great as it is
assumed. Statin treatment, both in rats and humans, appears
to affect the amount and synthesis of all mevalonate
pathway lipids [128,187–191]. CoQ amounts are decreased
in heart, muscle and liver after mevinolin treatment of rats,
indicating the importance of a decreased FPP pool on the
trans-prenyltransferase reaction [192]. Inhibition of squa-
lene synthase by squalestatin-1, which increases the FPP
pool, elevates CoQ synthesis both in tissue culture cells and
in rats in vivo [193,194].
Metabolites and intermediates function commonly as
regulatory substances for metabolic pathways, but none is
described so far for CoQ biosynthesis. A good candidate for
such a role is farnesol or one of its metabolites, e.g., farnesyl
esters, hydroxyfarnesol, farnesoic acid or dicarboxylic acids.
Farnesol is suggested to be involved in cell growth, phos-
phatidylcholine synthesis, ROS generation, apoptosis,
HMG-CoA reductase degradation, regulation of protein
kinase C and Ca2+ channels, and additional functions will
most probably appear in the future [195–197]. There are
also other candidates for a regulatory function in CoQ
biosynthesis. These are the biosynthetic intermediates or
their modified forms such as the partially substituted ring
structure without side chain, like vanillic acid. Metabolites
are also produced upon ultraviolet irradiation and after lipid
peroxidation in membranes, if the CoQ is present in oxi-
dized form [60,198]. Some of these products may be of
considerable interest in future studies.
Hormones are the well-established regulators of a large
number of tissue functions and CoQ is not an exception
from this rule. Very few studies are made in this field but it
is known that growth hormone, thyroxine, cortisone, adren-
aline and dehydroepiandrosterone treatments increase the
CoQ amount in rat liver [199]. Administration of thiouracil,
inhibitor of thyroid hormone production, decreases the lipid
concentration in liver [200]. Exposure of rodents to cold
temperature at 4jC increases liver CoQ [201]. It remains to
be investigated whether this increase is under hormonal
control.
Rats which receive protein-free diet exhibit a decreased
CoQ content in liver and heart but not in kidney, spleen and
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problem is naturally that these changes are not selective
but affecting a number of other biosynthetic systems and,
consequently, it may be difficult to relate functional mod-
ifications to CoQ deficiency.
Endurance exercise training increases CoQ concentration
in rat muscle on weight basis [203,204]. It appears that this
elevation is mainly explained by the increase of the mito-
chondrial mass. In human, 4 days of high intensity training
does not elevate CoQ content in the exposed muscles [205].
Dietary CoQ10 appears in the plasma but not in the skeletal
muscle or in mitochondria isolated from the muscle of the
control or training group.
Contrary to the situation with cholesterol, dietary and
diurnal variations do not appear to modify the tissue CoQ
content. Dietary vitamin A deficiency increases while vita-
min A administration decreases CoQ amount in liver
[200,206]. Selenium deficiency in rat decreases CoQ con-
tent in the liver by 50%, and some decrease also occurs in
heart and kidney but not in muscle [207]. Interestingly, the
decrease in liver does not affect plasma membranes which
exhibit an elevated CoQ content [208]. a-T and CoQ levels
in blood and tissues appear to be modified in a parallel
fashion which is probably expected because of the close
functional relationships between these two lipids. Upon
dietary administration of vitamin E, not only the vitamin
itself but also CoQ is increased in blood and liver [209]. On
the other hand, vitamin E-deficient diet decreases the
concentration of both lipids. When these lipids are supplied
together in the diet, the efficiency of the uptake is increased
in liver and spleen but no uptake was observed in heart,
kidney, muscle and brain [210]. On the other hand, higher
amount of CoQ was found in mouse heart, skeletal muscle,
kidney, brain and liver upon CoQ administration and the
uptake of CoQ was lowered when not only this lipid but also
a-T was included in the diet [211]. The differences seen in
these studies could be due to the method of administration,
composition of basal diet and the strain used. In hyper-
lipidemic patients not only blood triglycerides but also both
CoQ and a-T are increased [212]. When these patients were
treated with gemfibrozil, blood lipids were normalized and a
parallel decrease of both CoQ and a-T was observed. CoQ
diet in humans increases not only this administered lipid in
monocytes but also that of a-T [88]. In prion diseases of
mice both lipids are greatly increased in the brain [213]. The
close relationship in the parallel modifications of the two
antioxidant lipids is probably a biological necessity. CoQ
can regenerate a-T in vitro and thereby protect it from being
decomposed by a second radical attack, and it is therefore
reasonable that these two antioxidants act in concert [214].7. Enzymatic reduction of CoQ
For the antioxidant function of reduced CoQ, it is of great
importance that the reduced form can be regenerated at allcellular locations [303,304]. Several investigators have so
far studied the regeneration of CoQ and different CoQ
reductases have been suggested as reduction enzymes. It
was proposed that there is a cytosolic NADPH-dependent
CoQ reductase which is different from the mitochondrial
NADH-CoQ reductase and DT diaphorase as it is rotenone-
and dicumarol-resistant [215,216]. The most studied en-
zyme so far is DT-diaphorase, a cytosolic homodimeric
enzyme [217,218]. This enzyme has been shown to possess
the capacity to reduce CoQ but it is less efficient for longer
isoprenoid side chain length, i.e. those with 9 or 10 isoprene
units [219].
Recently, it has been shown in vitro that the enzymes
lipoamide dehydrogenase, thioredoxin reductase and gluta-
thione reductase efficiently could reduce coenzyme Q10
[220–222] (Nordman, T. Bjo¨rnstedt, M. Olsson, J.M.,
unpublished data). These FAD-containing enzymes are
homodimeric with subunits that have a molecular weight
of about 55 kDa and belong to a family of pyridine
nucleotide disulfide oxidoreductases [223–225]. Lipoamide
dehydrogenase is mainly known to participate in the three
a-ketoacid complexes located in the inner mitochondrial
membrane [226], however, this enzyme and the other two
oxidoreductases are present also in the extra-mitochondrial
space. All three enzymes can reduce lipoic acid to its
antioxidant form dihydrolipoic acid. In turn, dihydrolipoic
acid was demonstrated to be able to reduce CoQ [227].
Although thioredoxin reductase belongs to the same family
as lipoamide dehydrogenase, there are crucial structural
differences affecting the functions of this enzyme. The C-
terminal part of thioredoxin reductase is in comparison with
lipoamide dehydrogenase elongated with about 20 amino
acids that contain a cysteine and a selenocysteine adjacent to
each other [228]. The incorporation of selenium as seleno-
cysteine has been suggested to be facilitated by isopente-
nylation of the tRNAser/sec via the mevalonate pathway (see
above) [125]. The exceptionally broad substrate specificity
is probably connected with this selenenylsulfide as it is
located close to the active disulfide site, consisting of the
conserved sequence Cys-Val-Asn-Val-Gly-Cys, at the N-
terminal of the other subunit [228]. It is obvious that these
enzyme systems are connected and contribute to an elevated
level of resistance against oxidative stress in the cell.8. Dietary uptake
CoQ is taken up from the intestine into the circulation
with a low rate, only about 2–4% can be recovered [229].
The mechanism of uptake is not studied in detail but since it
is found in the various lipoproteins, redistribution in the
circulation appears to occur. In the case of a-T, the liver
possesses a specific binding protein which delivers it back
to the circulation via VLDL for further transport to different
organs [230]. The limited amount of information available
indicates that VLDL synthesized in the ER–Golgi system
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is required for antioxidant protection but not for redistribu-
tion to tissues [171]. Tritium-labeled dietary CoQ in liver is
either metabolized or excreted into the bile and thereafter
removed from the body [111]. In liver, spleen, adrenals,
ovaries, arterial endothelium, blood monocytes and lym-
phocytes from rat, CoQ is taken up from the circulation
while the uptake by heart, pancreas, pituitary gland, testis
and thymus is very limited. No uptake is visible in kidney,
muscle, brain, thyroid gland and blood polynuclear cells.
Uptake into the brain was observed in an investigation and it
cannot be excluded that the particular conditions used in this
study influence the results [232]. Species difference is
probably a deciding factor as in mice dietary CoQ appear
in various organs [231].
We have tried to improve the uptake of CoQ by admin-
istering two synthesized derivatives, disuccinylated (SQ)
and diacetylated CoQ (AQ) [233]. This method of admin-
istration has been described for a-T earlier [234]. The
objective was to maximize the plasma concentration of
CoQ and hence induce CoQ uptake into tissues. The plasma
levels of CoQ were indeed increased when SQ or AQ were
administered in comparison with non-derivatized CoQ.
However, none of the treatments showed any increase of
the lipid uptake into various tissues. Furthermore, SQ and
AQ were recovered in the plasma, liver and spleen as
underivatized CoQ, indicating the presence of highly effec-
tive esterases in the circulation and the intestine.
The uptake mechanism of CoQ from the blood into
tissues is not yet studied. Like cholesterol and a-T, LDL-
receptor may be one of the mediators since organs such as
adrenals and ovaries are rich in this receptor. This mecha-
nism of uptake is probably not the only one since in some
organs the receptor level and the degree of uptake are
different. Another possibility is that a CoQ-specific receptor
or binding protein is operating.
The limited uptake of external CoQ by animal tissues is
explained by its distribution, cellular location and functional
requirements. The localization of the lipid in the central
hydrophobic portion make membranes saturated and there is
no functional requirement or possibility to place more lipids
into the limited space. Since all type of cells have the CoQ
biosynthetic pathway, no external lipid is required under
normal conditions [235]. In fact, labeled CoQ taken up by
the liver does not appear in the mitochondria where more
than 80% of the endogenous lipid is found [111]. It is
distributed mainly in non-membranous luminal compart-
ments, preferentially in lysosomes [110]. The situation is
however different when the lipid is missing and the mem-
brane has the capacity, at least theoretically, to accept the
lipid. This situation is well documented in children with
genetic deficiency of CoQ synthesis [236]. These cases,
where there is almost complete lack of the lipid in fibro-
blasts and lymphoblasts, are associated with severe neuronal
and muscular symptoms. Dietary CoQ improves dramati-
cally the physical and intellectual capacities by restoringdeficient mitochondrial respiration. Another case is patients
with cardiomyopathy who exhibit low levels of CoQ in
heart biopsy samples [237–239]. After CoQ supplementa-
tion, the uptake is higher in severe heart disease in compar-
ison with the uptake in mild disease. Consequently, uptake
and proper tissue and cellular distribution of external CoQ
take place also in animal and humans, presupposing that
there is a requirement. If this is not the case, CoQ is either
not taken up, or it appears in cells mainly in the lumen of
some organelles. It is, however, possible that this non-
membranous lipid is functionally active. It is not clear
how CoQ deficiency is defined and when a decrease in
amount affects a function. In 1-year-old rats the amount of
CoQ is decreased in most tissues but the uptake into organs
upon dietary administration is not higher than in young rats
[233].
Administration of an exogenous substance may have
consequences for the production of the endogenous product.
In vivo labeling of endogenous CoQ with 3H-mevalonate
demonstrated that there is no product inhibition upon dietary
administration of the lipid [192]. In some studies, obviously
depending on the experimental conditions, an increase in
endogenous CoQ9 in rodents was described upon supple-
mentation of CoQ10 [231,232,241]. A possible explanation
is that the exogenous lipid is metabolized and some of the
breakdown products act as stimulatory agents on the bio-
synthetic mechanism.
The above discussion dealt with the direct organ uptake
of CoQ and its consequences. However, one has to keep in
mind that direct cellular uptake is not the only possibility for
action. The established way of action for many substances
does not require entrance into the cell. Signal transduction,
redox signaling, acting as primary ligand or secondary
transducer are the possibilities for such action by CoQ.
Influence on organ circulation and effect on the vascular
system are other possibilities since this lipid is taken up to
the blood. CoQ in the circulation may effect the production
of cytokines and interleukines, change the levels of adhe-
sion molecules and modify the production of prostaglandin
and leukotriene metabolites. The presence of this antioxi-
dant in the gastrointestinal system is an efficient way to
prevent formation of interactive free radicals. Even small
amounts of metabolites originating from CoQ, either from
normal catabolism or by other ways (e.g. radiation or
oxidation), may have considerable influence on many pro-
cesses considering the effects of many drugs after metabo-
lism. In this way, it may turn out that in spite of the limited
organ uptake, dietary CoQ has an important influence on
organ metabolism and function.9. Catabolism
CoQ has a high catabolic rate which is indicated by the
relatively short half-life, T1/2 (Table 6). The half-life varies
among tissues and it ranges between 49 and 125 h [242].
Table 6
Half-life of CoQ in rat tissues and spinach
Hours
Liver 79
Heart 59
Kidney 125
Stomach 72
Thyroid 49
Colon 54
Muscle 50
Intestine 54
Pancreas 94
Testis 50
Thymus 104
Spleen 64
Brain 90
Spinach 30
Data taken from Thelin et al. [242] and Wanke et al. [244].
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tissues which is, however, not the case in brain [243]. In this
organ both cholesterol and dolichol have a very high T1/2,
4080 and 1010 h, respectively, while it is 90 h for CoQ. This
finding demonstrates the importance of CoQ in the brain
and also shows the operation of terminal regulation in the
mevalonate pathway. Despite of the same initial reactions
leading to FPP, the rates of biosynthesis for the three lipids
are completely different. The relatively rapid breakdown of
CoQ is not only an event in animal cells but also occurs in
plants [244].
The catabolism of CoQ has been studied only to a limited
extent. Breakdown products isolated from urine and feces of
rat and guinea pig were characterized using mass spectrom-
etry and it was found that the main products have an intact,Fig. 10. Metabolites of [3H]CoQ in urine and feces. The insert in upper right corner
[111].fully substituted ring [245,246]. Using dietary CoQ7 in rat
and guinea pig, it has been suggested that the liver degrades
CoQ by initial N-oxidation and subsequent h-oxidations of
the side chain. The main product identified in the urine had
an aromatic ring, the side chain was shortened to 5–7 carbon
atoms and the N-end was carboxylated. When [3H]CoQ10
was injected to rats, radioactive water-soluble metabolites
could be isolated from all those organs which take up the
administered lipid [111]. The metabolites were found mainly
in the urine, but also recovered in the feces (discharged
through the bile), where even considerable amounts of non-
metabolized [3H]CoQ10 were found (Fig. 10).
At HPLC analysis of the urine extracts, two main
metabolites were isolated and both of them gave a signal
at m/z 389 in mass spectrometry. Upon fragmentation, two
signals at m/z 79 and 80 appeared, corresponding to PO3 (m/
z 79) and HPO3 (m/z 80). The main metabolite in the urine,
isolated by Nakamura et al. [246], in the phosphorylated
form has a calculated molecular weight of 389 which is
probably the major breakdown product of CoQ (Fig. 10,
insert). The two major products isolated on HPLC with
identical molecular weight are most probably the same
products but phosphorylated either at carbon 4 or alterna-
tively at carbon 1.
By analysis of metabolites in the bile of guinea pig, it
was found that conjugation occurred by glucuronidation
which derivatives appeared in the feces [246]. In contrast to
many other organs, the liver has a high glucuronidation
capacity and this type of conjugation obviously takes place
also in the liver for CoQ metabolites [247]. Conjugation of
breakdown products by phosphorylation is not a common
mechanism, but it is necessary in this case since thisshows the main phosphorylated metabolite. Data taken from Bentinger et al.
Fig. 11. Effect of a 6-week treatment with peroxisomal inducers on CoQ
content in various organs. Data taken from A˚berg et al. [251,252].
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occurs in all tissues. It is also possible that minor products
are conjugated by other mechanisms, such as sulfation or
glutathione conjugation. Further studies will be necessary to
establish the mechanism of the catabolism and identification
of enzymes participating in this process.
Both gas chromatography-mass fragmentography and
HPLC analyses have demonstrated that the metabolites
isolated after injection of labeled CoQ are identical with
the metabolites present in the urine produced after endog-
enous catabolism [111,246]. CoQ is synthesized in all cells
of the animal organism and the lipid is also broken down in
all cells. Before the products are discharged to the circula-
tion, they are conjugated by phosphorylation to make them
more hydrophilic. These metabolites are transported in the
blood to the kidney where they are excreted by the glomer-
ular–tubular system. In liver the main form of conjugation
is glucuronidation and the discharge system is the bile–
feces route.10. Induction of CoQ biosynthesis
Lipid metabolism is regulated in a great extent by
peroxisomes and this organelle has a high ability of prolif-
eration. A large number of structurally different natural and
synthetic compounds are known as peroxisomal inducers,
such as hypolipidemic and anti-inflammatory drugs, some
solvents, herbicides, plasticizers, surfactants and food fla-
vors [248,249]. Increased numbers of peroxisomes are also
observed at high-fat diet, vitamin E deficiency, cold adap-
tation, diabetes and at increased level of dehydroepiandros-
terone. Fibrates are commonly used drugs for treatment of
hyperlipidemia to decrease mainly blood triglycerides. In
humans there is also an induction of some peroxisomal
enzymes but no increase in the number of peroxisomes
[250].
When rodents are treated with peroxisomal inducers,
CoQ amount increases in various organs [251,252]. Among
the most effective inducers in rat is the plasticizer di(eth-
ylhexyl)phthalate (DEHP), which after 6 weeks of admin-
istration in the diet increases CoQ amount in the liver by
five times (Fig. 11). There is also an increase in other
organs, such as heart, muscle and blood but not in brain.
Other inducers, clofibrate, salicylic acid and dehydroepian-
drosterone, also give similar but less pronounced effects.
The inducer is species-specific and in mouse the highest
induction is obtained by administration of perfluorooctanoic
acid [248]. The elevated levels of CoQ are the result of
increased synthesis while the breakdown rate is unaffected
[240]. In agreement with the enhanced biosynthesis is the
finding that in vitro activities of trans-prenyltransferase and
nonaprenyl-4-hydroxybenzoate transferase are up-regulated
[253]. This is of importance since one of these enzymes is
considered to be rate-limiting in the biosynthesis of CoQ. In
young rats there is a manifold activation of fatty acid h-oxidation in the liver upon DEHP treatment which remains
high also in old (17-month-old) animals [240]. Contrarily,
the induction of CoQ amount of 42-day-old rats is as high as
sevenfold, but in 17-month-old rats the induction of CoQ is
completely absent. Consequently, other factors that are also
altered during aging control the induction of CoQ biosyn-
thesis by peroxisomal inducers.
Cold exposure of rats elevates the amounts of CoQ in the
liver threefold after 3 weeks [201]. In mice the induction is
60% and restricted to the liver [254]. In vivo incorporation
of [3H]mevalonate demonstrates that the changes are elicited
by an increased biosynthesis of the lipid.
10.1. Transcriptional regulation of lipid biosynthesis
Nuclear hormone receptors are ligand-dependent DNA
binding transcription factors that exert control on gene
expression. They make up a superfamily of more than 150
members that are divided into two groups, the steroid
receptor family and the non-steroid receptor family. Nuclear
hormone receptors probably arose from preexisting protein
modules during evolution and can be linked back structur-
ally to Pex11p, a peroxisomal membrane protein in unicel-
lular eukaryotes [255]. Nuclear receptors share common
structure/function domains, i.e. a variable N-terminal re-
gion, a conserved DNA binding domain (DBD), a con-
served ligand binding domain and a variable C-terminal
region [256]. The DBD targets the receptor to specific DNA
sequences or response elements and is composed of two
highly conserved zinc fingers generated by two cysteine-
rich motifs. Nuclear receptors form monomers, homodimers
and heterodimers and regulate gene expression by altering
chromatin structure, by interacting directly with the compo-
nents of the pre-initiation complex or by recruiting cofac-
tors. These cofactors lack DBD but are able to activate or
repress transcription by enhancing or inhibiting interactions
between the DNA binding transcription factors and the pre-
initiation complex.
Peroxisomal inducers are a class of compounds that act
as ligands to the steroid receptor family of peroxisomal
Table 7
RXRa and PPARa involvement in coenzyme Q metabolism
Constitutive
biosynthesis
Induction by
the peroxisomal
inducer DEHP
Induction by
cold exposure
RXRa required not required required
PPARa not required required not required
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When ligands bind to PPAR, it dimerizes with another
receptor, the retinoid X receptor (RXRa, h and g) and the
binding of the ligand–receptor complex to its cognate
response element can activate or repress specific transcrip-
tion [258]. PPARa affects genes including those encoding
apolipoproteins, lipoprotein lipase, fatty acid transport pro-
tein, peroxisomal and mitochondrial fatty acid metabolizing
enzymes and bile acid synthesizing enzymes [259–261].
Several chemicals such as hypolipidemic drugs, phthalates
and fatty acids can act as ligands to PPARa while the ligand
to RXR is 9-cis retinoic acid. RXR is able to form hetero-
dimers with a variety of hormone and orphan receptors
[262–265]. The dimerization partner includes RXR itself,
the retinoic acid receptor, the vitamin D receptor, the thyroid
hormone receptor, PPAR and orphan receptors. These het-
erodimers bind to direct repeat elements with spacings
varying from one to five nucleotides [266]. RXR probably
exists in cells as monomers in equilibrium with heterodi-
merized RXRs. Under in vivo conditions, the different
nuclear hormone receptors compete for binding to RXR,
bringing about a possible mechanism for crosstalk. Silenc-
ing of gene transcription can occur both in the absence of
ligands and in the presence of additional co-repressors
[267].
10.2. Influence of PPAR and RXR on CoQ biosynthesis
The experiments performed with peroxisomal inducers
clearly indicate that nuclear receptors are involved in the
regulation of CoQ metabolism. By utilizing PPARa-null
mice, it was possible to investigate the involvement of
PPARa in activation of CoQ biosynthesis [253]. Disruption
of the PPARa gene results in mice that are refractory to the
pleiotropic responses to inducers, but does not exhibit any
gross phenotypic defects [268]. Both the PPARa-null and
wild-type mice had similar amounts of tissue CoQ and also
cholesterol and dolichol [253]. Upon administration of
DEHP, there was no induction of CoQ in the null mice.
As described before, the rate of biosynthesis rather than the
rate of breakdown was altered by administration of
inducers [240]. Also trans-prenyltransferase and nonap-
renyl-4-hydroxybenzoate transferase activities were up-reg-
ulated after peroxisomal induction in the wild type, but not
in the PPARa-null mice. The induction of CoQ in different
tissues followed the expression of PPARa in these tissues
[269]. Since neither of these two genes nor their promoters
are identified in mammals, it was not possible to investi-
gate whether PPARa-RXR acted directly on the CoQ
genes or if the response to peroxisomal inducers was
indirect.
Recently, a hepatocyte-specific RXRa-deficient mouse
(RXRa-def) was produced [270]. These mice are different
from the PPARa-null mice in several aspects. RXRa
deficiency results in an induction of mRNA for several
apolipoproteins, serum cholesterol and triglyceride levels,which is not seen in the PPARa-null mice [271]. Inves-
tigations of these mice revealed that RXRa-def mice have
only half of the CoQ concentration in the liver in compar-
ison with the controls while both cholesterol and dolichol
levels were unchanged [254]. Also, the RXRa-def mice
have a decreased in vivo incorporation of [3H]mevalonate
into CoQ when compared to wild-type mice. On the other
hand, the induction of hepatic CoQ after exposure to DEHP
is present in the RXRa-def mice. In the kidney, which does
not have a dysfunctional RXR, CoQ concentration and
biosynthesis is equal to the control in all aspects.
Nuclear receptors are also involved in the CoQ induction
upon cold exposure. PPARa-null mice had an increased
amount of this lipid in the liver after cold treatment while
the RXRa-def mice did not respond to the cold treatment
[254]. These data further support the suggested presence of
one or several response elements in the promoters of CoQ
biosynthetic genes.
The role of nuclear receptors in CoQ metabolism is
summarized in Table 7. RXRa regulates the amount of
CoQ in liver and probably is required for the basal
transcription of genes involved in CoQ biosynthesis and
for its induction upon cold treatment, however, it is not
involved in the elevated biosynthesis during treatment with
peroxisomal inducer. PPARa is neither required for the
basal biosynthesis of the lipid nor for its induction by cold
exposure, but is necessary for the increase at treatment
with peroxisomal inducer. RXR is operating as a hetero-
dimer, but we have at present no information on the exact
nature of the other receptor. Some of the candidates are the
liver X and farnesol X receptors since both are related to
lipid metabolism associated with the mevalonate pathway.
Further studies have to answer on a number of questions
concerning the involvement of transcription factors in CoQ
biosynthesis. It appears also that neither PPARa nor
RXRa is involved in the basic synthesis of cholesterol
and dolichol.11. From E. coli to human
Almost all knowledge in the field of CoQ distribution,
metabolism, synthesis and function originate from studies
performed on bacteria, yeast, C. elegans and, to some
limited extent, on rats. A single cell or less complex
organism is always advantageous to identify and character-
ize cellular processes and in most cases it is the only way to
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to extrapolate the findings to human for four reasons.
1. The metabolism of CoQ in higher organisms obviously
differs in a great extent from that of single-cell
organisms. Even if the synthesis and breakdown may
follow a similar pattern, considerable differences are
established concerning individual steps and, in particular,
the regulation of these reactions.
2. In higher organisms the uptake of dietary CoQ is very
limited under normal conditions and the uptake from the
blood to the organs is also restricted, especially into
mitochondria. In one-cell systems the uptake is not
regulated by a complex mechanism but follows an uptake
mechanism valid to most of lipids present in the
environment.
3. Animal tissues have a number of efficient systems to
reduce oxidized CoQ, which maintains a high antioxidant
level. This is probably not the case in C. elegans, where
dietary CoQ shortens life-span and, additionally, proba-
bly increases electron transport, resulting in release of
ROS [272]. However, life-long administration of CoQ
does not affect life-span of rats and mice [273,274].
4. Like other active cellular components, the action of CoQ
is not restricted to only a few actions such as serving as
redox mediator and antioxidant. CoQ interferes with h2-
integrins and complement receptors of monocytes,
changes hormone levels, affects uptake of a-T, may
modify the production of leukotrienes and prostaglandins
and regulates signaling systems by metabolites. In this
way, contrary to single-cell organisms, a variety of
metabolic interferences occur in mammals as a result of
species-specific response.12. Aging
Changes in lipid composition during aging are of great
interest since these modifications have significant impact
on the physico-chemical structure of membranes and
function of the integral enzymes and their metabolic
processes. The mevalonate pathway lipids display a char-
acteristic behavior during aging [275]. In Table 8, human
heart and pancreas from a 2-day old newborns are com-
pared with persons of age 20 and 80 years. The CoQ
content is greatly increased in the first 20 years of life,Table 8
Mevalonate pathway lipids in human heart and pancreas during aging
Organ Age (years) Coenzyme Q Dolichol
(% of 2-day-old
Heart 20 300 132
80 129 605
Pancreas 20 228 5450
80 71 17,502
Data taken from Kalen et al. [275].followed by a decrease in a variable extent and in some
organs at 80 years of age may be lower than at birth. Both
dolichol and dolichyl-P increase during the whole life at a
great extent. An important question that is not yet
addressed is, however, to which extent these modifications
represent a real deficiency in the membrane structure or
are attributed to a change in cellular organization. Only a
limited extent of decrease of CoQ content was observed in
synaptic and non-synaptic mitochondria from different
brain regions, and in mitochondria in liver and heart of
rats during aging [276,277]. Mitochondria prepared from
tissues of aged mice do not exhibit changes in CoQ levels
with the exception of skeletal muscle [278]. It would be of
great importance to establish whether CoQ is decreased in
individual cellular membranes or if the modification is the
consequence of a decrease in number of mitochondria.
CoQ in adult tissues is found mostly in reduced form but
the extent of reduction in aged tissue is not yet determined.
If the oxidized portion is increased, this may favor the
catabolic activities leading to an accelerated breakdown
and decrease in the amount of CoQ in the tissue.13. Diseases
The CoQ content is altered in a number of diseases, of
which the decrease in cardiomyopathies and degenerative
muscle diseases are the most studied [279–282]. CoQ is
commonly used for treatment of cardiomyopathy and there
is substantial evidence that heart function is improved upon
administration of the lipid [283]. CoQ reaches the heart via
the blood but is taken up only to a limited extent, and the
uptake is probably not sufficient to account for all of the
observed improvements. Other mechanisms, either of sig-
naling type or production of mediators, appear to exist
which do not require the entrance of CoQ into the cell.
Hyperplastic noduli is the first stage during development
of chemically induced hepatocellular cancer in rat and
during this first stage the amount of CoQ increases (Table
9) [284,285]. Interestingly, the amount of CoQ in the
mitochondria is stable, and the change in CoQ concentra-
tions is attributed to the extra-mitochondrial compartments.
During the first stage of the disease there is increased
oxidative stress which has been suggested to induce an
adaptive response, resulting in that the cell protects itself by
raising the concentrations of antioxidants [286]. In thehuman)
Dolichyl-P Cholesterol Phospholipids
400 59 82
2364 82 109
176 50 140
500 68 181
Table 9
Mevalonate pathway lipids in various pathological conditions
CoQ Dolichol Dolichyl-P Cholesterol References
(% of control)
Noduli, rat liver 196 671 175 148 [284,285]
Noduli [284]
Mitochondria 104 116 52
Microsomes 693 474 83
Lysosomes 261 84 106
Cancer, rat liver 76 105 204 190 (Olsson, J.M.,
unpublished
data)
Cancer, human
liver
40 889 94 212 [287]
Cardiomyopathy,
human heart
40-80 [237–239]
Alzheimer’s
disease, human
brain
130 56 172 102 [293]
Prion disease,
mice brain
250 67 158 103 [213]
Niemann–Pick
type C disease,
mouse liver
65 95 267 1100 [296]
Diabetes, type 2,
rat liver
140 [298]
Diabetes, type 2,
rat testis,
mitochondria
125 [297]
Mevinolin
treatment of
rat
[192]
Heart 82 72 60 104
Muscle 83 75 68 92
Liver 89 134 91 85
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Upon progression of the disease, manifest cancer develops
and the amount of CoQ decreases to only 40% in human
and 76% in rat [287] (Olsson, J.M., unpublished data).
Cholesterol is doubled in fully developed cancerous liver.
In biopsy samples from human heart, a significant
decrease of the CoQ content in cardiomyopathy was found
and the decrease could be related to the severity of the
disease [237–239]. In these biopsy samples, uptake of CoQ
was found after dietary treatment with the lipid.
CoQ has been suggested to be involved in neurodegen-
erative diseases such as Huntington’s disease, Parkinson’s
disease and amyotrophic lateral sclerosis [288–290]. In
both experimental models and human patients, beneficial
effects have been observed after supplementation with CoQ
[291,292]. Changes in lipid concentrations are extensive in
Alzheimer’s disease in humans and in scrapie-caused prion
disease in mice [213,293]. The amount of CoQ is greatly
increased in both instances, especially in the prion disease,
about 250%. a-T, the other main lipid-soluble antioxidant, is
also increased under these conditions. It is now generally
accepted that increased production of free radicals is an
important feature during the development of these diseases,
and it is not surprising that cellular protection is induced tocounteract these radicals [294]. It has also been suggested
that Alzheimer’s and prion diseases—in spite of their
different appearances—have much in common in etiology
and development [295]. This possibility is further strength-
ened by the behavior of other mevalonate pathway lipids. In
both diseases, dolichol decreases, dolichyl-P increases and
cholesterol is unchanged throughout the process.
In a murine model of Niemann–Pick type C disease,
there is a massive accumulation of cholesterol in the liver. In
this disease dolichyl-P is greatly increased and CoQ is
lowered in a significant extent [296]. In experimental
diabetes, the concentration of CoQ in rat liver and in testis
mitochondria is elevated [297,298]. Statins are of great
interest as the most commonly used drugs for treatment of
hypercholesterolemia and it is recently established that they
are additionally decreasing the level of inflammatory cyto-
kines [299]. These drugs, however, have unwanted effects
by not only lowering CoQ levels in the blood but also by
causing other symptoms such as muscle disturbances [300].
The explanation is that statins interfere with various enzy-
matic steps of the mevalonate pathway lipid biosynthesis
since CoQ, dolichol and dolichyl-P in heart and muscle are
decreased upon treatment [192].
The importance of CoQ in the life of the living
organisms is illuminated most clearly by the number of
reports describing the genetic disorders in which CoQ
synthesis is impaired. Lowered lipid content in organs
causes serious metabolic disturbances but CoQ supplemen-
tation reestablishes mitochondrial and other functions. Our
primary goal in the near future should be to establish an
animal model with deficiency of the biosynthetic system.
Studies in such model could give valuable information on
the physiological role of CoQ and answer questions
concerning its complex involvement in various aspects of
the living organism.References
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